An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

It is a hallucinogenic drug, and is a controlled substance designed for use as an aesthetics. It also has now been touted for ...

"Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants ...

Johnson & Johnson's Spravato nasal spray has been FDA-approved as a stand-alone therapy for adults with treatment-resistant ...

Lorna Staines discusses a longitudinal population-based study examining the risks of using psychedelics in a naturalistic ...

The connection between M. morganii, inflammation, and depression aligns with earlier research. IL-6 has been repeatedly ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with ma ...

The Trump administration’s first drug pricing action — rescinding a Biden executive order encouraging Medicare to help lower ...